Overview

* CorMedix's preliminary Q3 2025 revenue beats expectations, driven by strong DefenCath utilization

* Company raises FY 2025 revenue guidance to at least $375 mln

* CorMedix ( CRMD ) expects $30 mln operating synergy before year-end 2025

Outlook

* CorMedix ( CRMD ) raises FY 2025 pro forma net revenue guidance to at least $375 mln

* Company expects $30 mln in synergies by end of 2025

* CorMedix ( CRMD ) projects year-end cash balance of approximately $100 mln

Result Drivers

* DEFENCATH UTILIZATION - Stronger than expected utilization of DefenCath drove revenue growth

* MELINTA INTEGRATION - Integration of Melinta portfolio contributed to increased revenue guidance

* COST SYNERGIES - Significant progress on Melinta integration with expected cost synergies

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $85 mln $66.13

Revenue mln (7

Analysts

)

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for CorMedix Inc ( CRMD ) is $20.50, about 50.3% above its October 17 closing price of $10.18

* The stock recently traded at 4 times the next 12-month earnings vs. a P/E of 9 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)